Details
Picaud, S., C. Wells, I. Felletar, D. Brotherton, S. Martin, P. Savitsky, B. Diez-Dacal, M. Philpott, C. Bountra, H. Lingard, O. Fedorov, S. Muller, P.E. Brennan, S. Knapp and P. Flippakopoulos (2013). “RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.” Prox Natl Acad Sci U.S.A. 110(49): 19754-19759 (Abstract)(Abstract)
McLure K.G., E.M. Gesner, L. Tsujikawa, O.A. Kharenko, S. Attwell, E. Campeau. S. Wasiak, A. Stein, A. White, E. Fontano, R.K. Suto, N.C. Wong, G.S. Wagner, H.C. Hansen and P.R. Young (2013). “RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist.” PLoS One 8(12): e83190 (Abstract)(Abstract)
Bailey D., R. Jahagirdar, A. Gordon, A. Hafiane, S. Campbell, S. Chatur, G.S. Wagner, H.C. Hansen, F.S. Chiacchia, J. Johansson, L. Krimbou, N.C. Wong, J. Genest (2010). “RVX-208: A small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo.” J Am Coll Cardiol 55(23): 2580-2589 (Abstract)(Abstract)
Nicholls, S.J., A. Gordon, J. Johannson, C.M. Ballantyne, P.J. Barter, H.B. Brewer, J.J. Kasterlein, N.C. Wong, M.R. Borgman, S.E. Nissen (2012). “ApoA-I induction as a potential cardioprotective strategy: Rationale for the SUSTAIN and ASSURE studies.” Cardiovasc Drugs Ther 26(2): 181-187 (Abstract)(Abstract)